Evidence map›Paper›PMID 30636888›Full record

ArticleJournal of inflammation research2019

Evaluation of cytokines in peripheral blood mononuclear cell supernatants for the diagnosis of tuberculosis.

Margaretha Sariko, Athanasia Maro, Jean Gratz, Eric Houpt, Riziki Kisonga, Stellah Mpagama, Scott Heysell, Blandina T Mmbaga, Tania A Thomas

Open access · goldAbstract read
In one paragraph

Article in Journal of inflammation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Margaretha SarikoKilimanjaro Clinical Research Institute, Moshi, Tanzania, m.sariko@kcri.ac.tz.
Athanasia MaroKilimanjaro Clinical Research Institute, Moshi, Tanzania, m.sariko@kcri.ac.tz.
Jean GratzKilimanjaro Clinical Research Institute, Moshi, Tanzania, m.sariko@kcri.ac.tz.
Eric HouptDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Riziki KisongaKilimanjaro Clinical Research Institute, Moshi, Tanzania, m.sariko@kcri.ac.tz.
Stellah MpagamaKilimanjaro Clinical Research Institute, Moshi, Tanzania, m.sariko@kcri.ac.tz.
Scott HeysellDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Blandina T MmbagaKilimanjaro Clinical Research Institute, Moshi, Tanzania, m.sariko@kcri.ac.tz.
Tania A ThomasDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Kilimanjaro Christian Medical Centre · TZUniversity of Virginia · US

Funding

Diagnostics and Pharmacotherapy for Severe Forms of TBU01AI115594 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYSELL, SCOTT K, HOUPT, ERIC R · 2015 to 2019
$3.0M
Global Infectious Disease Research Training Program at UVAD43TW006578 · FIC · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GUERRANT, RICHARD L · 2003 to 2018
$2.7M
Global Infectious Disease Research Training Program AwardD43TW008270 · FIC · UNIVERSITY OF VIRGINIA · PI HOUPT, ERIC R · 2010 to 2014
$735k
Improving Pediatric Tb Diagnosis and Management in TanzaniaK23AI097197 · NIAID · UNIVERSITY OF VIRGINIA · PI THOMAS, TANIA A · 2012 to 2016
$645k
FIC NIH HHS D43 TW006578FIC NIH HHS D43 TW008270NIAID NIH HHS K23 AI097197NIAID NIH HHS U01 AI115594
6 · The paper itself

Abstract

introductionThere is active interest in leveraging host immune responses as biomarkers of tuberculosis (TB) disease activity. We had previously evaluated an immunodiagnostic test called the antibody in lymphocyte supernatant (ALS) assay. Here, we aimed to evaluate a panel of inflammatory mediators and associate the responses with the ALS results to identify a biosignature to distinguish TB cases from controls. METHODOLOGY: In this case-control study, adults with TB were compared to controls who were hospitalized for non-infectious conditions. Blood was collected at baseline and after 4 weeks of TB treatment (from TB cases only). Peripheral blood mononuclear cells were isolated and cultured without antigenic stimulation for 72 hours. Inflammatory mediators were measured using the Multiplex cytokine kit and compared between TB cases and controls; among TB cases, responses were compared over time. ALS and inflammatory mediator results were evaluated using generalized discriminant analysis to identify the optimal biosignature to predict TB.

resultsWhen comparing inflammatory mediators between groups, IL-1ra, IL-1β, and granulocyte macrophage-colony stimulating factor (GM-CSF) were lower in TB cases (

conclusionOur results suggest that IL-1ra, IL-1β, and GM-CSF might be used as diagnostic biomarkers to distinguish between TB cases and non-TB cases. We could not identify a group of mediators that outperformed the diagnostic accuracy of the ALS alone.

Indexed as

biomarkerschemokinescytokinesdiagnosticsTB

Identifiers

PMID30636888
PMCPMC6307673
OpenAlexW2905630650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.